Abstract Details

Title Association of Serum Neurofilament Biomarker Levels with Quality of Life and Healthcare Utilization in Patients with Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P14 - Poster Session 14 (8:00 AM-9:00 AM)

Poster/Presentation
Number 9-021

Objective

To evaluate the relationship between serum-neurofilament (sNfL) and health outcomes (quality of life [QOL], treatment-persistence and healthcare resource use [HCRU]) in multiple sclerosis (MS) patients.

Background

sNfL is a soluble biomarker of neuro-axonal damage in MS and other neurological diseases. The longitudinal relationship between health outcomes including (QOL, persistence and HCRU) with sNfL has not been evaluated to date.

Design/Methods

Patients enrolled in Comprehensive Longitudinal Investigations in MS at Brigham and Women's Hospital (CLIMB) study (2010-2015) with sNfL and completed health outcome measurements at each visit were included. The patient-reported outcomes (PRO) included: MSQOL54, Center for Epidemiologic Studies Depression Rating Scale, Fatigue Impact Scale, Work-Productivity and Impairment. sNfL analysis was performed on stored serum samples using single-molecule array (SIMOA) assay (Quanterix). Data were analyzed using Pearson’s correlation with log-transformed sNFL values at baseline, and average over baseline, 12 and 24-months follow-up.

Results

A total of 304 MS patients with a mean age of 32.9 years, average EDSS of 1.6 (1.5) and baseline sNFL of 8.8 (range 1.23-78.3) pg/ml were enrolled in the cohort. Overall, baseline sNFL correlated with baseline MSQOL physical composite (p=0.035) and baseline EDSS (p=0.002). Other PRO measures at baseline did not show a significant relationship with baseline sNFL. Average of baseline and follow-up sNfL correlated with MSQOL physical-role limitations (p=0.043) and social-functioning (p=0.034) at 24-month follow-up. We found a trend for numerically higher sNfL levels in non-persistent patients compared to those who were persistent to treatment (11.13 vs 8.53 pg/ml, p=0.093) measured as average of baseline and 24-month values. Baseline NfL was associated number of intravenous steroid infusions (p=0.013) while average of baseline and 12 months NfL values was related to inpatient stays at 12-months (p=0.053).

Conclusions

sNFL is a patient-centric biomarker that correlated MS patient health outcomes and healthcare utilization measures in a real-world cohort.

Authors/Disclosures
Kristin M. Galetta, MD (Stanford University) PRESENTER	Dr. Galetta has received personal compensation in the range of $0-$499 for serving as a Speaker with Can Do MS.
	No disclosure on file
Brian C. Healy	The institution of Mr. Healy has received research support from Analysis Group. The institution of Mr. Healy has received research support from Bristol-Myers Squibb. The institution of Mr. Healy has received research support from Verily Life Sciences. The institution of Mr. Healy has received research support from Novartis. The institution of Mr. Healy has received research support from Merck Serono. The institution of Mr. Healy has received research support from Genzyme.
Bonnie Glanz (Brigham and Women'S Hospital)	The institution of Ms. Glanz has received research support from CMSC. The institution of Ms. Glanz has received research support from NIH.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Howard L. Weiner, MD (Brigham and Women'S Hospital)	Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
Tanuja Chitnis, MD, F�鶹��ýӳ�� (Brigham and Women's Hospital)	Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.

�鶹��ýӳ��

�鶹��ýӳ��